Shares of Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $51.26 and last traded at $51.26, with a volume of 0 shares changing hands. The stock had previously closed at $51.26.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a report on Monday, September 23rd.
View Our Latest Stock Analysis on BPMUF
Basilea Pharmaceutica Stock Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- What to Know About Investing in Penny Stocks
- 3 Momentum Trades for October With Ample Upside Ahead
- Investing In Automotive Stocks
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What is the Hang Seng index?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
